Form DEF 14A TSCAN THERAPEUTICS For: 17 April
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Tscan Therapeutics Inc (TCRX)
Tscan Therapeutics Inc stock price live, this page displays NASDAQ TCRX stock exchange data. View the TCRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Tscan Therapeutics Inc real time stock price chart below.
What Is the Tscan Therapeutics Inc Stock Price Today?
The Tscan Therapeutics Inc stock price today is 1.16.
What Is the Stock Symbol for Tscan Therapeutics Inc?
The stock symbol for Tscan Therapeutics Inc is "TCRX."
What Stock Exchange Does Tscan Therapeutics Inc Trade On?
Tscan Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Tscan Therapeutics Inc a Good Stock to Buy?
Determining whether Tscan Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TCRX quote. (ISIN: US89854M1018)
What Is the Tscan Therapeutics Inc Stock Price Today?
The Tscan Therapeutics Inc stock price today is 1.16.
What Is the Stock Symbol for Tscan Therapeutics Inc?
The stock symbol for Tscan Therapeutics Inc is "TCRX."
What Stock Exchange Does Tscan Therapeutics Inc Trade On?
Tscan Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Tscan Therapeutics Inc a Good Stock to Buy?
Determining whether Tscan Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TCRX quote. (ISIN: US89854M1018)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.13
1.20
52 wk Range
0.88
2.57
Earnings results expected in 11 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.131.20
52 wk Range
0.882.57
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TCRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
6.00
Upside
+417.24%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 8K Tscan Therapeutics Inc For: 2 April
- Investing.com
- Form DEF 14A TSCAN THERAPEUTICS For: 17 April
- Investing.com
- Form PRE 14A TSCAN THERAPEUTICS For: 7 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.00
(+417.24% Upside)
Earnings
Latest Release
Mar 04, 2026
EPS / Forecast
-0.18 / -0.27
Revenue / Forecast
2.57M / 2.04M
Compare TCRX to Peers and Sector
Metrics to compare | TCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTCRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −3.1x | −0.5x | |
PEG Ratio | −0.04 | −0.14 | 0.00 | |
Price/Book | 0.6x | 2.6x | 2.6x | |
Price / LTM Sales | 6.8x | 9.3x | 3.2x | |
Upside (Analyst Target) | - | 343.5% | 48.8% | |
Fair Value Upside | Unlock | 20.9% | 6.9% | Unlock |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Tscan Therapeutics (TCRX) Stock Price Today?
The Tscan Therapeutics stock price today is 1.16 USD.
What Stock Exchange Does Tscan Therapeutics Trade On?
Tscan Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Tscan Therapeutics?
The stock symbol for Tscan Therapeutics is "TCRX."
What Is the Tscan Therapeutics Market Cap?
As of today, Tscan Therapeutics market cap is 69.72M USD.
What Is Tscan Therapeutics's Earnings Per Share (TTM)?
The Tscan Therapeutics EPS (TTM) is -1.00.
When Is the Next Tscan Therapeutics Earnings Date?
Tscan Therapeutics will release its next earnings report on May 12, 2026.
From a Technical Analysis Perspective, Is TCRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Tscan Therapeutics Stock Split?
Tscan Therapeutics has split 0 times.
How Many Employees Does Tscan Therapeutics Have?
Tscan Therapeutics has 142 employees.
What is the current trading status of Tscan Therapeutics (TCRX)?
As of May 01, 2026, Tscan Therapeutics (TCRX) is trading at a price of 1.16 USD, with a previous close of 1.16 USD. The stock has fluctuated within a day range of 1.13 USD to 1.20 USD, while its 52-week range spans from 0.88 USD to 2.57 USD.
What Is Tscan Therapeutics (TCRX) Price Target According to Analysts?
The average 12-month price target for Tscan Therapeutics is 6.00 USD, with a high estimate of 7 USD and a low estimate of 5 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +417.24% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.